News & Updates
Filter by Specialty:
Potassium competitive acid blockers go toe-to-toe with PPI in gastric acid diseases
Vonoprazan, a potassium competitive acid blocker (PCAB), is better than proton pump inhibitors (PPI) for the treatment of Helicobacter pylori and erosive oesophagitis, according to a new meta-analysis.
Potassium competitive acid blockers go toe-to-toe with PPI in gastric acid diseases
21 Oct 2022
Risk management program cuts plasma triglycerides in T2D
A 2-week comprehensive risk-management regimen can successfully suppress levels of plasma triglycerides in patients with type 2 diabetes (T2D), a recent study reported.
Risk management program cuts plasma triglycerides in T2D
21 Oct 2022
Amphilimus- vs zotarolimus-eluting stents: Any preference in patients with diabetes?
Updated results of the SUGAR* trial showed that using polymer-free amphilimus-eluting stents (AES) was not a superior option to durable-polymer zotarolimus-eluting stents (ZES) in patients with diabetes mellitus who required percutaneous coronary intervention (PCI).
Amphilimus- vs zotarolimus-eluting stents: Any preference in patients with diabetes?
20 Oct 2022
Add-on docetaxel confers survival advantage in ICI-naïve NSCLC, with caveat
In the treatment of patients with ICI-naïve nonsmall cell lung cancer (NSCLC), adding the cytotoxic chemotherapy docetaxel to the immune-checkpoint inhibitor (ICI) nivolumab leads to a significantly longer survival, although at the expense of slightly elevated toxicity, according to the results of a phase II/III trial.
Add-on docetaxel confers survival advantage in ICI-naïve NSCLC, with caveat
20 Oct 2022
Circulating T cells tied to CVD risk in people with HIV infection
Subsets of peripheral circulating CD4 T cell among people with HIV infection (PWH) are predictive of incident cardiovascular disease (CVD), including heart failure and atherosclerotic CVD, reveals a study.